RPE65 and respiratory distress syndrome in premature infants: Voretigene neparvovec-rzyl (VN; AAV2-hRPE65v2) is the first ocular gene augmentation therapy approved by the FDA for IRDs caused by biallelic RPE65 mutations [24].